ストックスクリーナーアプリを入手
2.125
3.41%
0.075
前日終値:
$2.05
開ける：
$2.06
24時間の取引高:
3.63M
Relative Volume:
0.81
時価総額：
$427.64M
収益：
$116.33M
当期純損益:
$-209.25M
株価収益率:
-1.0024
EPS:
-2.12
ネットキャッシュフロー:
$-135.49M
1週間 パフォーマンス:
+2.42%
1か月 パフォーマンス:
+84.35%
6か月 パフォーマンス:
+16.48%
1年 パフォーマンス:
+20.45%
1日の値動き範囲:
$2.03
$2.15
1週間の範囲:
$2.00
$2.185
52週間の値動き範囲:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
名前
Esperion Therapeutics Inc
セクター
電話
734-887-3903
住所
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
ESPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.121 | 423.41M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
155.72 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.30 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.66 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
309.67 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-18 | 開始されました | Goldman | Neutral |
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-06-20 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-01 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | アップグレード | BofA Securities | Underperform → Buy |
| 2023-03-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-03-16 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 再開されました | BofA Securities | Neutral |
| 2023-02-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-02-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-19 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-12 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-09 | ダウングレード | Goldman | Neutral → Sell |
| 2021-01-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-10 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 再開されました | JP Morgan | Underweight |
| 2020-08-11 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 再開されました | BofA/Merrill | Buy |
| 2020-03-17 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-24 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-16 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-29 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | アップグレード | Goldman | Sell → Neutral |
| 2019-03-13 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 繰り返されました | Needham | Strong Buy |
| 2018-12-13 | 開始されました | Goldman | Sell |
| 2018-10-29 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 開始されました | BTIG Research | Buy |
| 2018-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2018-07-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-05-02 | ダウングレード | BofA/Merrill | Buy → Underperform |
すべてを表示
Esperion Therapeutics Inc (ESPR) 最新ニュース
Esperion rises after revenue beat, Q1 profitability expectation - MSN
Three Analyst Favorites with Potential for Further Gains: SkyWater Technology, Emergent BioSolutions, and More - AInvest
Detecting support and resistance levels for Esperion Therapeutics Inc.Stock Surge & Safe Entry Momentum Tips - Newser
Chart based analysis of Esperion Therapeutics Inc. trendsWeekly Market Report & AI Forecasted Entry/Exit Points - Newser
Is Esperion Therapeutics Inc. still worth holding after the dip2025 Short Interest & Community Consensus Picks - Newser
Esperion Therapeutics soars amid vague takeover speculation - MSN
Best data tools to analyze Esperion Therapeutics Inc. stockTrade Risk Report & Risk Controlled Daily Plans - Newser
Esperion Therapeutics Inc. stock outlook for YEARPortfolio Update Report & Stepwise Entry/Exit Trade Alerts - Newser
Is Esperion Therapeutics Inc. a Top Dividend Stock to Watch in 2025Market Movers & AI Based Trade Execution Alerts - Newser
Applying sector rotation models to Esperion Therapeutics Inc.Market Growth Summary & Free Low Drawdown Momentum Trade Ideas - Newser
Esperion Therapeutics (NASDAQ:ESPR) Upgraded at Wall Street Zen - Defense World
Pattern recognition hints at Esperion Therapeutics Inc. upsideStock Surge & Risk Adjusted Buy/Sell Alerts - Newser
What MACD signals say about Esperion Therapeutics Inc.July 2025 PostEarnings & Step-by-Step Swing Trade Plans - Newser
Real time scanner hits for Esperion Therapeutics Inc. explainedJuly 2025 Earnings & Smart Money Movement Alerts - Newser
Will Esperion Therapeutics Inc. price bounce be sustainableCEO Change & Daily Market Momentum Tracking - Newser
What the charts say about Esperion Therapeutics Inc. today2025 Price Targets & Long Hold Capital Preservation Tips - Newser
Is Esperion Therapeutics Inc. stock poised for growth2025 EndofYear Setup & Stock Portfolio Risk Control - Newser
Backtesting results for Esperion Therapeutics Inc. trading strategiesWeekly Gains Summary & Breakout Confirmation Trade Signals - Newser
Assessing Madrigal Pharmaceuticals' Long-Term Market Potential in the LDL-C Lowering Therapy Sector Amid Competitive Dynamics - AInvest
Is a relief rally coming for Esperion Therapeutics Inc. holdersDollar Strength & Free High Accuracy Swing Entry Alerts - Newser
Signal strength of Esperion Therapeutics Inc. stock in tech scannersJuly 2025 Update & Short-Term Trading Opportunity Alerts - Newser
Can Esperion Therapeutics Inc. Regain Momentum After BreakdownJuly 2025 Rallies & Safe Entry Trade Reports - beatles.ru
What earnings revisions data tells us about Esperion Therapeutics Inc.Quarterly Profit Review & Real-Time Buy Signal Notifications - Newser
Wall Street Zen Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Hold" - MarketBeat
Esperion Delays Q2 2025 Financial Report Filing - MSN
Competitive Positioning of Esperion Therapeutics Inc.: Is It Leading or LaggingFree Intraday Trend Analysis for Fast Gains - Newser
Published on: 2025-08-10 18:32:11 - beatles.ru
FY2025 EPS Estimates for ESPR Boosted by Cantor Fitzgerald - Defense World
Esperion Therapeutics Inc. At Decision Level — Rebound or ResistanceExpert Verified Stock Trade Ideas Backed by Data - beatles.ru
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises - MSN
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Hold at Wall Street Zen - Defense World
HC Wainwright Issues Positive Outlook for ESPR Earnings - Defense World
Published on: 2025-08-08 10:01:24 - beatles.ru
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) for New Employees - AInvest
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Esperion Grants 73,500 RSUs with 4-Year Vesting Schedule to Attract Top Talent - Stock Titan
Esperion Therapeutics’ Earnings Call Highlights Growth - The Globe and Mail
Esperion (ESPR) Q2 Revenue Jumps 12% - AOL.com
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Call Transcript - Insider Monkey
Esperion expects sustainable profitability in Q1 2026 as double-digit growth continues - MSN
Esperion Therapeutics: Q2 Earnings Snapshot - New Haven Register
What institutional flow reveals about Esperion Therapeutics Inc.Long-Term Stock Growth Forecast Insights - Newser
Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ... By GuruFocus - Investing.com Canada
Esperion Therapeutics Reports Strong Q2 2025 Growth - TipRanks
Esperion Therapeutics Inc (ESPR) 財務データ
収益
当期純利益
現金流量
EPS
Esperion Therapeutics Inc (ESPR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Halladay Benjamin | Chief Financial Officer |
Jul 17 '25 |
Sale |
1.11 |
11 |
12 |
474,462 |
0.45%
大文字化:
|
ボリューム (24 時間):